Zobrazeno 1 - 10
of 16
pro vyhledávání: ''
Autor:
Ryo Takahashi, Naoki Hiki, Masato Nagino, Manabu Ohashi, Kensei Yamaguchi, Yosuke Kano, Takeshi Sano, Satoshi Ida, Koshi Kumagai, Souya Nunobe, Keisho Chin
Publikováno v:
Gastric Cancer. 22:1256-1262
Adjuvant S-1 monotherapy prolongs the survival of patients with pathological stage II or III gastric cancer undergoing D2 gastrectomy. This therapeutic regimen is standard in Japan. Unfortunately, some patients who undergo this treatment suffer from
Autor:
Kojiro Eto, Daisuke Takahari, Keisho Chin, Naoki Hiki, Yasuo Tsuda, Souya Nunobe, Yoshiaki Shoji, Kensei Yamaguchi, Manabu Ohashi, Itaru Yasufuku, Koshi Kumagai, Takeshi Sano, Yosuke Kano, Satoshi Ida
Publikováno v:
Gastric Cancer. 21:1024-1030
One-year adjuvant S-1 monotherapy following D2 gastrectomy has been the Japanese treatment standard for pathological stage II or III gastric cancer since the Adjuvant Chemotherapy Trial of S-1 for Gastric Cancer (ACTS-GC) was concluded in 2007. Trial
Autor:
Ichiro Takemasa, Hiroyuki Ohnuma, Tetsuji Takayama, Tamotsu Sagawa, Hiroshi Miyamoto, Takayuki Nobuoka, Mitsuo Shimada, Yasuo Takahashi, Koshi Fujikawa, Minoru Takahashi, Shinich Katsuki, Masahiro Hirakawa, Junji Kato, Yutaka Okagawa, Koichi Okamoto, Yasushi Sato, Syouhei Kikuch, Minami Shinya, Uemura Naoki, Masahiro Maeda
Publikováno v:
Gastric Cancer. 20:517-526
Conversion therapy is an option for unresectable metastatic gastric cancer when distant metastases are controlled by chemotherapy; however, the feasibility and efficacy remain unclear. This study aimed to assess the feasibility and efficacy of conver
Autor:
Shinichi Sakuramoto, Hitoshi Katai, Mitsuru Sasako, Hiroshi Imamura, Koji Kitada, Masanori Terashima, Atsushi Ochiai, Issei Kurahashi, Wataru Ichikawa, Takeshi Sano
Publikováno v:
Gastric Cancer
Background Exploratory biomarker analysis was conducted to identify factors related to the outcomes of patients with stage II/III gastric cancer using data from the Adjuvant Chemotherapy Trial of S-1 for Gastric Cancer, which was a randomized control
Autor:
Byung Sik Kim, Min-Hee Ryu, Sook Ryun Park, Yoon-Koo Kang, Sun-Young Kong, Jeong Hwan Yook, Moon-Won Yoo, Jae Ho Jeong, Baek-Yeol Ryoo, Yongchel Ahn, Beom Su Kim
Publikováno v:
Gastric Cancer. 20:146-155
Oral fluoropyrimidine S-1 contains tegafur, which is metabolized to 5-fluorouracil by cytochrome P450 2A6 (CYP2A6). We here examined associations between CYP2A6 polymorphisms and treatment outcomes of adjuvant S-1 in gastric cancer patients. Patients
Autor:
Narikazu Boku, Tomoya Yokota, Nozomu Machida, Hiroya Kashiwagi, Keita Mori, Akiko Todaka, Takahiro Tsushima, Hirofumi Yasui, Akira Fukutomi, Satoshi Hamauchi, Masao Ichinose, Kentaro Yamazaki, Yusuke Onozawa, Hiroyuki Tabuse
Publikováno v:
Gastric Cancer. 19:894-901
Watering eyes is a common late adverse event associated with S-1 chemotherapy; however, the frequency and predictive factors are not known.This study included 304 consecutive gastric cancer patients treated with adjuvant S-1 monotherapy for 1 year at
Autor:
Nozomu Fuse, Shogo Nomura, Makoto Tahara, Emiko Nagahisa-Oku, Takashi Kojima, Takayuki Yoshino, Tomonori Yano, Takahide Sasaki, Toshihiko Doi, Atsushi Ohtsu
Publikováno v:
Gastric Cancer. 16:324-328
The Response Evaluation Criteria in Solid Tumors (RECIST) was revised in 2009, based on a large dataset of 6512 patients from 16 trials. However, no gastric cancer patients were included in those data. The purpose of this study was to clarify the dif
Autor:
Takaki Yoshikawa, Takashi Ogata, Haruhiko Cho, Hiroshi Kuwabara, Akira Tsuburaya, Tsutomu Hayashi, Toru Aoyama, Yo Mikayama
Publikováno v:
Gastric Cancer. 16:133-139
The factors that affect the 6-month continuation of adjuvant chemotherapy with S-1 have not been fully evaluated. The objective of this retrospective study was to clarify the risk factors for 6-month continuation of S-1 adjuvant chemotherapy.The stud
Autor:
Katsuyoshi Hatakeyama, Shin-ichi Kosugi, Tatsuo Kanda, Yoichi Ajioka, Kazuhito Yajima, Takashi Ishikawa
Publikováno v:
Gastric Cancer. 15:235-244
Current advances in chemotherapy provide opportunities for stage IV gastric cancer patients with distant metastasis to undergo potentially curable resection. There are, however, few data on gastrectomy as a secondary surgery aimed at rendering such p
Autor:
Takafumi Watanabe, Takashi Ogata, Toru Aoyama, Takaki Yoshikawa, Haruhiko Cho, Akira Tsuburaya, Tsutomu Hayashi
Publikováno v:
Gastric Cancer. 15:76-82
The safety and feasibility of administering S-1 adjuvant chemotherapy for gastric cancer has not been fully evaluated in elderly patients.This retrospective study selected patients who underwent curative D2 surgery for gastric cancer, were diagnosed